1 Torres-Guerrero E, Quintanilla-Cedillo MR, Ruiz-Esmenjaud J, Arenas R. Leishmaniasis: a review. F1000Res. 2017;6:750.
2 Desjeux P. Leishmaniasis: current situation and new perspectives. Comp Immunol Microbiol Infect Dis. 2004;27(5):305–18.
3 Guerin PJ, Olliaro P, Sundar S, Boelaert M, Croft SL, Desjeux P, et al. Visceral leishmaniasis: current status of control, diagnosis, and treatment, and a proposed research and development agenda. Lancet Infect Dis. 2002;2(8):494–501.
4 Antinori S, Calattini S, Longhi E, Bestetti G, Piolini R, Magni C, et al. Clinical use of polymerase chain reaction performed on peripheral blood and bone marrow samples for the diagnosis and monitoring of visceral leishmaniasis in HIV-infected and HIV-uninfected patients: a single-center, 8-year experience in Italy and review of the literature. Clin Infect Dis. 2007;44(12):1602–10.
5 Burza S, Croft SL, Boelaert M. Leishmaniasis. Lancet. 2018;392(10151):951–70.
6 Gradoni L, Rogelio L, Mourad M. Manual on case management and surveillance of the leishmaniasis in the WHO European Region. World Health Organization Regional Office for Europe, Hg. Kopenhagen: The WHO Regional Office for Europe; 2017.
7 van Griensven J, Diro E, Lopez-Velez R, Boelaert M, Lynen L, Zijlstra E, et al. HIV-1 protease inhibitors for treatment of visceral leishmaniasis in HIV-co-infected individuals. Lancet Infect Dis. 2013;13(3):251–9.
8 Aronson N, Herwaldt BL, Libman M, Pearson R, Lopez-Velez R, Weina P, et al. Diagnosis and treatment of leishmaniasis: Clinical practice guidelines by the Infectious Diseases Society of America (IDSA) and the American Society of Tropical Medicine and Hygiene (ASTMH). Clin Infect Dis. 2016;63(12):1539–57.
9 Cotton JA. The expanding world of human leishmaniasis. Trends Parasitol. 2017;33(5):341–4.
10 Antoniou M, Haralambous C, Mazeris A, Pratlong F, Dedet JP, Soteriadou K. Leishmania donovani leishmaniasis in Cyprus. Lancet Infect Dis. 2009;9(2):76–7.
11 Strelkova MV, Ponirovsky EN, Morozov EN, Zhirenkina EN, Razakov SA, Kovalenko DA, et al. A narrative review of visceral leishmaniasis in Armenia, Azerbaijan, Georgia, Kazakhstan, Kyrgyzstan, Tajikistan, Turkmenistan, Uzbekistan, the Crimean Peninsula and Southern Russia. Parasit Vectors. 2015;8:330.
12 Clementi A, Battaglia G, Floris M, Castellino P, Ronco C, Cruz DN. Renal involvement in leishmaniasis: a review of the literature. NDT Plus. 2011;4(3):147–52.
13 de Ruiter CM, van der Veer C, Leeflang MM, Deborggraeve S, Lucas C, Adams ER. Molecular tools for diagnosis of visceral leishmaniasis: systematic review and meta-analysis of diagnostic test accuracy. J Clin Microbiol. 2014;52(9):3147–55.
14 van Griensven J, Diro E. Visceral Leishmaniasis: Recent advances in diagnostics and treatment regimens. Infect Dis Clin North Am. 2019;33(1):79–99.
15 Foroutan M, Dalvand S, Khademvatan S, Majidiani H, Khalkhali H, Masoumifard S, Shamsaddin G. A systematic review and meta-analysis of the prevalence of Leishmania infection in blood donors. Transfus Apher Sci. 2017;56(4):544–51.
16 Asfaram S, Fakhar M, Soosaraei M, Hosseini Teshnizi S, Mardani A, Banimostafavi ES, Ziaei Hezarjaribi H. Global status of visceral leishmanial infection among blood donors: A systematic review and meta-analysis. Transfus Apher Sci. 2017;56(5):748–54.
17 Neumayr A. Antiparasitic Treatment Recommendations. 2. Aufl. Schweizerische Fachgesellschaft für Tropen- und Reisemedizin FMH, Hg. Hamburg: tredition GmbH; 2018.
18 Sundar S, Chakravarty J. An update on pharmacotherapy for leishmaniasis. Expert Opin Pharmacother. 2015;16(2):237–52.
19 Alves F, Bilbe G, Blesson S, Goyal V, Monnerat S, Mowbray C, et al. Recent development of visceral leishmaniasis treatments: Successes, pitfalls, and perspectives. Clin Microbiol Rev. 2018;31(4):e00048-18.
20 Diro E, Blesson S, Edwards T, Ritmeijer K, Fikre H, Admassu H, et al. A randomized trial of AmBisome monotherapy and AmBisome and miltefosine combination to treat visceral leishmaniasis in HIV co-infected patients in Ethiopia. PLoS Negl Trop Dis. 2019;13(1):e0006988.